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Background: Data regarding management of pediatric persons with hemophilia A
(PwHA) with factor VIII (FVIII) inhibitors are limited. This prospective noninterven-
tional study (NCT02476942) evaluated annualized bleeding rates (ABRs), safety, and
health-related quality of life (HRQoL) in pediatric PwHAwith FVIII inhibitors.
Procedure:PwHAaged<12 yearswith current FVIII inhibitors and high-titer inhibitor
history were enrolled. Participants remained on usual treatment; no interventions
were applied. Outcomes included ABR, safety, and HRQoL.
Results: Twenty-four PwHA aged 2-11 years (median 7.5) were enrolled and mon-
itored for 8.7-44.1 weeks (median 23.4). In the episodic (n = 10) and prophylactic
(n = 14) groups, respectively, 121 of 185 (65.4%) and 101 of 186 (54.3%) bleeds were
treated using activated prothrombin complex concentrate (aPCC) and/or recombinant
activated FVII (rFVIIa). ABRs (95% confidence interval) were 19.4 (13.2-28.4) and 18.5
(14.2-24.0) for treated bleeds, and 32.7 (20.5-52.2) and 33.1 (22.4-48.9) for all bleeds,
respectively. Most prophylactic group participants (92.9%) were prescribed aPCC;
50%adhered to their prescribed treatment regimen. Adherence to prophylactic rFVIIa
was not assessed. Serious adverse events included hemarthrosis (12.5%) and mouth
Abbreviations: ABR, annualized bleed rate; Adapted Inhib-QoL, Adapted Inhibitor-Specific Quality of Life Assessment with Aspects of Caregiver Burden; AE, adverse event; aPCC, activated
prothrombin complex concentrate; BMQ, bleed andmedication questionnaire; BPA, bypassing agent; CI, confidence interval; FVIII, factor VIII; HA, hemophilia A; Haemo-QoL SF,
Haemophilia-Specific Quality of Life Assessment Instrument for Children and Adolescents Short Form; HRQoL, health-related quality of life; IQR, interquartile range; ITI, immune tolerance
induction; NIS, noninterventional study; PwHA, persons with hemophilia A; rFVIIa, recombinant activated factor VII; SAE, serious adverse event
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hemorrhage (12.5%); the most common nonserious adverse event was viral upper res-
piratory tract infection (12.5%). HRQoL showed functional impairment at baseline;
scores remained stable throughout, with little intergroup variation.
Conclusions: ABRs remained high in pediatric PwHA with inhibitors receiving stan-
dard treatment. This study demonstrates the need formore effective treatments, with
reduced treatment burden, to prevent bleeds, increase prophylaxis adherence, and
improve patient outcomes.
KEYWORDS
blood coagulation factor inhibitors, emicizumab, FVIII, health-related quality of life, hemophilia A,
noninterventional study
1 INTRODUCTION
Management of pediatric persons with hemophilia and factor VIII
(FVIII) inhibitors is challenging; acute bleeding episodes are dif-
ficult to treat and prophylaxis has limited efficacy, leaving indi-
viduals at higher risk of severe bleed-related complications com-
pared with persons with hemophilia without FVIII inhibitors receiving
FVIII prophylaxis.1 Inadequately managed repeated bleeding episodes
result in joint and muscle deterioration, significant physical disability,
impaired function, and chronic pain, often within the first one to two
decades of life,2,3 and can affect the perceived health-related qual-
ity of life (HRQoL) of pediatric persons with hemophilia and FVIII
inhibitors.4
Additionally, the burden of caring for a child with hemophilia and
FVIII inhibitors dramatically impacts the caregiver, more than caring
for a child with hemophilia without FVIII inhibitors.5,6
In pediatric persons with hemophilia and FVIII inhibitors, the goal is
to prevent joint bleeding, reduce the risk of bleed-related joint dam-
age, and maintain or improve HRQoL.7 Few therapeutic options are
available for persons with hemophilia A (PwHA) and FVIII inhibitors,
which typically arise at a median age of ≤3 years in developed coun-
tries. Immune tolerance induction (ITI) involves frequent, prolonged
infusions of FVIII to eradicate inhibitors.8,9 Treatmentmay be required
for many years, but is not always effective10,11 and inhibitors may
recur.12 Bypassing agents (BPAs), used to manage bleeds prophylac-
tically or episodically, have short half-lives, limited effectiveness,13,14
and burdensome administration.8,15 In pediatrics, the need for fre-
quent intravenous infusions often necessitates use of central venous
access devices, which are associated with increased risk of infections
or thrombosis.16,17
While data on the challenges of managing pediatric PwHA with
inhibitors in a real-world setting are limited, data from theDOSE study
indicate high bleeding rates (median 13 bleeding episodes reported
in the previous year) in PwHA (median [range] age 16.2 [1.6-60.9]
years) that interfere with the daily activities of both patients and their
caregivers.18 Notably, bleed days were associated with significantly
worse HRQoL than nonbleed days in this observational study.18 More
information regarding the management of pediatric PwHA with FVIII
inhibitors would help guide the development of novel treatments for
optimizedmanagement.
A multicenter noninterventional study (NIS; NCT02476942) was
designed to prospectively collect data on bleeding events, treatment,
safety, andHRQoL inPwHAwithorwithoutFVIII inhibitors treatedper
local clinical practice. Data from adolescent/adult PwHA with (Cohort
A) and without inhibitors (Cohort C) in this NIS have been previ-
ously reported.19,20 Here, we report data from pediatric PwHA with
inhibitors (Cohort B).
Eligible participants were subsequently enrolled in HAVEN 2
(NCT02795767), a Phase III trial of emicizumab (HEMLIBRA®, F.
Hoffmann-La Roche Ltd, Basel, Switzerland), allowing intraindi-
vidual comparisons of bleed-related endpoints before and during
emicizumab prophylaxis.21 Emicizumab, a recombinant, humanized,
bispecific, monoclonal antibody, improves hemostasis by bridging
activated factor IX and factor X to replace the function of missing
activated FVIII.22 Emicizumab is approved in many countries for
routine prophylaxis in PwHA with or without FVIII inhibitors of all
ages.23,24
2 METHODS
2.1 Study setting and design
The setting and design of this global, multicenter, prospective NIS
have been described previously19 (Figure S1). Pediatric participants
(Cohort B) were enrolled from February 2016 to July 2016 in China,
Costa Rica, Germany, Spain, Italy, Japan, USA, and South Africa. The
NIS was approved by local ethics review groups; legal guardians of
pediatric participants signed informed consent, andparticipants signed
informed assent where applicable.
Based on the minimum number of participants initially planned for
HAVEN 2, the enrollment target for the NIS Cohort B was 30 partici-
pants. Participants were enrolled in the episodic or prophylactic group
based on their current regimen. Treatments and assessments were
conducted per routine clinical practice; no additional clinical or labora-
tory assessments were required. Study completion occurred when the
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last participant was followed for 24 weeks, discontinued treatment, or
switched to HAVEN 2.
2.2 Study participants
Eligible participantswere aged<12yearswith congenital hemophiliaA
(HA) with high-titer FVIII inhibitor history (≥5 Bethesda units/mL) and
current FVIII inhibitors, receiving either episodic or prophylactic BPAs,
and had experienced ≥4 bleeds in the last 6 months (participants aged
≥2-11 years) or ≥2 bleeds in the previous 3 months (participants aged
<2 years). Exclusion criteria were as follows: abnormal hematologic,
hepatic or renal function; known thromboembolic disease; bleeding
disorder other than hemophilia A; ongoing ITI with FVIII or FVIII pro-
phylaxis; active significant infection; or known hypersensitivity against
globulin preparations.19 Participants who had previously undergone
ITI that was not successful could participate in this study. Eligibility cri-
teria andmethodsof data collection and followupwere similar to those
in HAVEN 2.21
2.3 Endpoints
The primary endpoint was the number of treated bleeds over time
(bleeding rate). Other bleed-related endpoints included bleeding rates
for all bleeds (treated and untreated) as well as the cause (traumatic,
spontaneous, surgery/procedure), type (joint, muscle, other), and loca-
tion (eg, elbow, ankle, knee, calf, buttock, other). Secondary endpoints
were typeof coagulationproduct, reason for treatment, adverseevents
(AEs), and HRQoL.
2.4 Data collection
Demographic data and medical history from participants’ medical
records, AEs, and bleeds that qualified as serious AEs (SAEs; eg, life
threatening or required hospitalization), and use of concomitant med-
ications (other than coagulation products before/during the study)
were recorded in the electronic case report form.
Bleeding events and hemostatic treatments were recorded daily
by the participants’ legally authorized representative through a bleed
and medication questionnaire (BMQ) provided by the sponsor in an
electronic handheld device. Details of the BMQ have been previously
described.19 Briefly, the BMQ included questions on bleed type, loca-
tion, cause, and timing. No additional procedures to ascertain the valid-
ity of bleeding events as reported by participants or their caregivers
were implemented. Participants reported use of hemophilia medica-
tion (timing and dose) and reason for treatment (bleed, usual prophy-
laxis, preventative dose before activity, or preventative dose for proce-
dure/surgery). If participants missed an entry for a particular day, they
could retrospectively enter data for up to 7 succeeding days.
Children aged 8-11 years self-reported HRQoL using the
Haemophilia-Specific Quality of Life Assessment Instrument for
Children and Adolescents Short Form (Haemo-QoL SF)25 monthly via
the electronic handheld device; caregivers of children aged 0-11 years
completed the Adapted Inhibitor-Specific Quality of Life Assessment
with Aspects of Caregiver Burden (Adapted Inhib-QoL)26 to obtain
proxy HRQoL and aspects of the burden of hemophilia on the care-
giver (Supporting Information Methods). Both HRQoL measures are
scored from 0 to 100, with higher scores being reflective of greater
impairments in HRQoL.25,26
2.5 Data sharing statement
Qualified researchers may request access to individual patient-level
data through the clinical study data request platform (https://vivli.
org/). Further details on Roche’s criteria for eligible studies are avail-
able at https://vivli.org/members/ourmembers/. For further details
on Roche’s Global Policy on the Sharing of Clinical Information




There was no predefined hypothesis testing; all analyses were descrip-
tive. Results are presented for all participants and separately by treat-
ment regimen (episodic or prophylactic). Efficacy period (for bleed-
related endpoints) and observation time (for safety reporting) were
defined as the time between the day of handheld device activation
and the date of study withdrawal or completion, whichever occurred
first. Bleed definitions (adapted from standard criteria)27 are consis-
tent with HAVEN 2 (Supporting InformationMethods).
Annualized bleeding rate (ABR) was derived using two methods.
Model-based ABR was estimated via a negative binomial regression
model, which accounted for different follow-up times (efficacy peri-
ods) as an offset in the model, and is reported with 95% confidence
intervals (CIs). Median ABR was also calculated using the following
equation: ABR = [(number of bleeds)/(number of days during efficacy
period)] × 365.25, and is reported with interquartile ranges (IQRs). A
summary of the incidence, cause, type, and location of bleeds was pro-
vided.
Participants were considered compliant with completing the BMQ
if the questionnaire was completed at least every 8 days; reminders to
enter datawere sent daily via the electronic handheld device. The total
number of days that participants were expected to complete the ques-
tionnaire was used to determine BMQ compliance rate.
Adherence with prophylaxis was evaluated in terms of dose admin-
istered and frequency of administration, and included participants in
the prophylactic group with activated prothrombin complex concen-
trate (aPCC) prescription for >3 months during the study. Adherence
with recombinant activated FVII (rFVIIa) was not assessed because
only two participants were prescribed rFVIIa prophylaxis. Adherence
with prescribed frequency of drug administration was categorized by
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n= 14 All N= 24
Age
Median (range) age, years 6.5 (2-11) 8.0 (3-11) 7.5 (2-11)
0 to<2, n (%) 0 0 0
2 to<6, n (%) 4 (40) 2 (14) 6 (25)
6 to<12, n (%) 6 (60) 12 (86) 18 (75)
Race, n (%)
Caucasian 3 (30) 8 (57) 11 (46)
Asian 5 (50) 3 (21) 8 (33)
Black/African
American
1 (10) 1 (7.1) 2 (8.3)
Multiple 0 1 (7.1) 1 (4.2)







Mean (SD) 9.9 (4.6) 6.0 (2.9) 7.5 (4.1)




1 (10) 11 (79) 12 (50)
aExcludes one patient due to corresponding bleeds occurring in the previ-
ous 4 months, not 6 months, as reported by investigators based on medical
records.
the proportion of weeks participants administered the required num-
ber of injections (high, >80%; moderate, 60-80%; low, <60%).28,29
Adherence with prescribed dose was categorized by the proportion of
administered doses versus prescribed dose (high,≥80%; low,<80%).
3 RESULTS
3.1 Study population
Twenty-four male PwHA with FVIII inhibitors aged 2-11 (median 7.5)
years were enrolled: 10 receiving episodic treatment and 14 receiv-
ing prophylaxis with BPAs (Table 1). Both the median (range) efficacy
period andmedian (range) observation time in theepisodic andprophy-
lactic groups, respectively, were 31.2 (21.3-44.1) and 17.9 (8.7-36.4)
weeks. All participants completed the study; six (60%) in the episodic
group and 13 (92.9%) in the prophylactic group were eligible to subse-
quently enter HAVEN 2 (Figure S2).
Medical conditions were reported in three (30%) participants in the
episodic group and seven (50%) in the prophylactic group (Table S1);
conditions reported inmore thanoneparticipantwere seasonal allergy,
attention-deficit hyperactivity disorder, and dermatitis. Proportions of
participants receiving concomitant medications other than hemophilia
medicationswere similar in the episodic (70%) and prophylaxis (71.4%)
groups (Table S2); the most common medications were analgesics,
nonsteroidal antiinflammatory drugs, and iron formulations. Compli-
ance with BMQ reporting was high and stable during the study; 89.6
and 95.3% of the patient-reported outcome questionnaires were com-
pleted in the episodic and prophylactic groups, respectively.
3.2 Bleed outcomes
Overall, 371 bleeds were experienced by 24 participants; 222 were
treated (53.6% spontaneous; 46.4% traumatic; Figure S3). For all
bleeds, the proportion of traumatic bleeds was 55.7% in the episodic
group and 44.1% in the prophylactic group (Figure S3).
For treated bleeds, model-based ABR (95%CI) was 19.4 (13.2-28.4)
and 18.5 (14.2-24.0) in the episodic and prophylactic groups, respec-
tively; median ABR (IQR) was 18.1 (14.2-24.8) and 16.1 (11.0-25.8)
(Figure 1; Table S3). For all bleeds in the episodic and prophylactic
groups, respectively, model-based ABR (95% CI) was 32.7 (20.5-52.2)
and 33.1 (22.4-48.9); median ABR (IQR) was 26.2 (14.5-31.9) and 17.2
(12.4-44.5). Most participants (80%, episodic; 85.7%, prophylaxis) had
an ABR >10 for treated bleeds. In both treatment groups, ∼40% of all
bleedswere untreated, themajority (85.3%) of whichwere reported as
“other” bleeds (bleeds by location presented in Table S4).
Themost frequent typesof treatedbleedswere joint bleeds, primar-
ily in the elbow and ankle (Table S4; Figure S4). In the episodic and pro-
phylactic groups, treated joint bleed model-based ABR (95% CI) was
10.4 (5.2-20.9) and 8.3 (5.7-12.0), and median ABR (IQR) was 5.4 (4.3-
14.8) and 6.2 (3.1-11.5), respectively (Table S3).
3.3 Management with hemophilia treatments
Most participants (83.3%) received aPCC and 50% received rFVIIa
(Table 2);∼33% in each groupusedboth treatments. In the episodic and
prophylactic groups, respectively, participants used amedian (range) of
28 (3-124) and 134 (11-321) doses of aPCC and 25 (1-93) and 21 (3-
193) doses of rFVIIa (Table 2).
In the episodic group, most participants used aPCC or rFVIIa for
treatment of bleeding (70 and 60%, respectively); fewer used aPCC or
rFVIIa prior to activity (30 and10%, respectively), and 10%used rFVIIa
prior to a procedure/surgery (Table 2). One participant switched from
episodic to prophylactic treatment halfway through his efficacy period,
but was included in the episodic group for data analysis.
In the prophylactic group, most participants (92.9%) used aPCC for
treatment of bleeding, whereas only 28.6% used rFVIIa. Few patients
used aPCC or rFVIIa prior to activity (14.3 and 7.1%, respectively);
14.3% used rFVIIa prior to a procedure/surgery (Table 2).
3.4 Adherence with prophylaxis
Adherence with prophylaxis was evaluated in participants in the pro-
phylactic groupwho received aPCC (12/14); participantswho received
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F IGURE 1 Annualized bleed rates.a A, Model-based ABR (95%CI). B, Calculatedmedian ABR (IQR). aAll bleeds comprised both treated and
untreated bleeds. All bleeds were included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to
surgery/procedure were excluded. An event was considered a treated bleed if coagulation factors were administered to treat signs of bleeding
(pain, swelling, etc), irrespective of the time between the bleed and the treatment. bNegative binomial regressionmodel. ABR, annualized bleeding
rate; CI, confidence interval; IQR, interquartile range
rFVIIa (2/14) were excluded due to the small patient number. Partici-
pants received a median (range) of 7.45 (0.4-14.0) aPCC doses/week,
including those administered for treatment of breakthrough bleeds.
The median (range) administered dose of aPCC prescribed for prophy-
laxis was 69.30 (44.0-90.6) units/kg. The median proportion of weeks
that participants were adherent to their prescribed frequency of aPCC
administration was 91% (range 20-100%). Overall, 58.3% of partici-
pants adhered to their prescribed frequency of aPCC administration
for >80% of study weeks, 8.3% for 60-80% of study weeks, and 33.3%
for <60% of study weeks. All participants except one (91.7%) adhered
to their prescribed dose of aPCC, ofwhom50%also adhered to the fre-
quency of dosing (Table 3).
3.5 Safety outcomes
The only AE reported in ≥3 participants in either treatment arm was
upper respiratory tract infection (3/14 prophylactic group). Approxi-
mately 30% of participants in each group experienced SAEs (Table 4).
Themost common SAEswere hemarthrosis (1/10 episodic group; 2/14
prophylactic group) and mouth hemorrhage (2/10 episodic therapy;
1/14 prophylaxis).
Six traumatic bleeds that qualified as SAEs were reported in four
participants: one event in one participant in the episodic group and five
events in three participants in the prophylactic group. The most fre-
quent cause of trauma was strenuous activity. There were no fatal AEs
and no participant was withdrawn from the study due to AEs.
3.6 HRQoL
The Haemo-QoL SF was completed by three of four eligible partici-
pants (aged 8-11 years) in the episodic group, and eight of eight partici-
pants in theprophylactic group. TheAdapted Inhib-QoLwas completed
by all caregivers (n= 24).
Mean scores at baseline across the majority of HRQoL domains on
both measures indicated functional impairments. The greatest impair-
ments were seen in the “Sports & School” and “Family” domains for the
Haemo-QoL SF (Table S5), and the “Dealing with Inhibitor” domain for
the Adapted Inhib-QoL (Table S6).
Mean scores did not change substantially over the study period
for “Physical Health” (Figure 2) or other domains (Figure S5), whether
reported by children (Haemo-QoL SF) or caregivers (Adapted Inhib-
QoL).
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TABLE 2 Hemophilia treatments





Total participants with≥1 treatment, n (%) 10 (100) 14 (100) 24 (100)
Reason for treatment
Treatment for bleed 10 (100) 13 (93) 23 (96)
Usual prophylaxis dose 1 (10)
b
14 (100) 15 (63)
Preventive dose before activity 4 (40) 2 (14) 6 (25)
Preventative dose for procedure/surgery 1 (10) 2 (14) 3 (13)
Participants treatedwith aPCC, n (%) 7 (70) 13 (93) 20 (83)
Number of doses, median (range)
c
28 (3-124) 134 (12-321) 103 (3-321)
aPCC cumulative dose, median (range), U/kg
c
2344.4 (96-11 395) 8920.7 (638-15 757) 6656.1 (96-15 757)
Number of bleeds treatedwith aPCC only, n 72 68 140
aPCC dose administered per bleed, median (range), U/kg 140.9 (15.3-1581.4) 360.8 (33.3-2378.4) 216.1 (15.3-2378.4)
Number of aPCC doses per bleed, median (range) 2.0 (1-17) 4.0 (1-26) 3.0 (1-26)
Reason for treatment
Treatment for bleed 7 (70) 13 (93) 20 (83)
Usual prophylaxis dose 1 (10)
b
13 (93) 14 (58)
Preventive dose before activity 3 (30) 2 (14) 5 (21)
Preventative dose for procedure/surgery 0 0 0
Participants treatedwith rFVIIa, n (%)
d
6 (60) 6 (43) 12 (50)
Number of doses, median (range)
c
25 (1-93) 21 (3-197) 21 (1-197)
rFVIIa cumulative dose, median (range), µg/kgc 7453.7 (71-26 390) 2928.1 (632-24 035) 5313.1 (71-26 390)
Number of bleeds treatedwith rFVIIa only, n 45 15 60
rFVIIa dose administered per bleed, median (range), µg/kg 603.5 (156.3-4400.0) 533.3 (174.4-5945.9) 591.7 (156.3-5945.9)
Number of rFVIIa doses per bleed, median (range) 2.0 (1-42) 2.0 (1-52) 2.0 (1-52)
Reason for treatment
Treatment for bleed 6 (60) 4 (29) 10 (42)
Usual prophylaxis dose 1 (10)
b
2 (14) 3 (13)
Preventive dose before activity 1 (10) 1 (7.1) 2 (8.3)
Preventative dose for procedure/surgery 1 (10) 2 (14) 3 (13)
Participants treatedwith both aPCC and rFVIIa, n (%) 3 (30) 5 (36) 8 (33)
Number of bleeds treatedwith aPCC and rFVIIa, n 4 18 22
aPCC dose administered per bleed, median (range), U/kg 245.8 (66.7-1357.1) 66.7 (58.0-1648.4) 66.7 (58.0-1648.4)
Number of aPCC doses per bleed, median (range) 4.0 (1-16) 1.0 (1-20) 1.0 (1-20)
rFVIIa dose administered per bleed, median (range), µg/kg 2301.9 (71.4-3703.7) 1171.1 (110.0-2600.0) 1171.1 (71.4-3703.7)
Number of rFVIIa doses per bleed, median (range) 1.0 (1-9) 6.0 (1-12) 5.5 (1-12)
Abbreviations: aPCC, activated prothrombin complex concentrate; FVIII, factor VIII; ITI, immune tolerance induction; NIS, noninterventional study; rFVIIa,
recombinant activated factor VII.
aOne participant in the prophylactic group initiated ITI during the NIS and received standard half-life FVIII.
bOne participant in the episodic group reported usual prophylaxis doses for both aPCC and rFVIIa due to switching to prophylactic treatment during theNIS.
cAll hemophilia-related treatments, including treatment for bleeds, usual prophylaxis, and preventative doses.
dProphylactic treatment with rFVIIa is not defined in the drug label.
4 DISCUSSION
This study prospectively collected data from a pediatric cohort of
PwHA with FVIII inhibitors treated episodically or prophylactically
with BPAs per local clinical practice.
The current standard-of-care treatment for pediatric PwHA who
have developed inhibitors to FVIII includes a trial of ITI, where
available.30 Half of the participants in this NIS had previously under-
gone ITI (Table 1).
Bleeding rates in the NIS were high, with no notable difference
between the episodic andprophylaxis groups for treated and all bleeds.
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TABLE 3 Adherence with aPCC prophylaxis by frequency of
prescribed dose

















Abbreviation: aPCC, activated prothrombin complex concentrate.





n= 14 All N= 24
Total number of AEs 12 28 40
Total participants
experiencing≥1AE, n (%)
6 (60) 9 (64) 15 (63)
Fatal AE 0 0 0
Serious AE 3 (30) 4 (29) 7 (29)






Hemarthrosis 1 (10) 2 (14)
b
3 (13)
Mouth hemorrhage 2 (20) 1 (7.1) 3 (13)
Muscle hemorrhage 0 2 (14) 2 (8.3)
Upper gastrointestinal
hemorrhage
0 1 (7.1) 1 (4.2)
Puncture site
hemorrhage
0 1 (7.1) 1 (4.2)
Hematuria 0 1 (7.1) 1 (4.2)
Hematoma 0 1 (7.1) 1 (4.2)
Abbreviations: AE, adverse event; HA, hemophilia A; SAE, serious adverse
event.
aSome participants reported more than one SAE; bleeds were not reported
as AEs unless they qualified as serious AEs.
bIn the prophylaxis group, two participants experienced nine serious AEs of
hemarthrosis; two events (22%) were caused by trauma and seven (78%)
were spontaneous bleeds.
The similar bleeding rates may have been confounded by several fac-
tors; in particular, the requirement for patients to have experienced a
minimum number of bleeds to participate in the study, regardless of
prior treatment regimen, and the tendency to prescribe prophylactic
therapy to patients with a higher frequency of bleeding.While this NIS
contributes additional bleed data in line with previous studies,14,31-33
direct comparisons with the literature are not straightforward due to
the lack of standardized bleed definitions and methodologies for data
collection.
There was a high incidence of treated joint bleeds in both the
episodic and prophylactic groups. Of all bleeds, most were reported
as “other” possibly due to the high incidence of bruises or hematomas
resulting from high physical activity in children. Similar proportions of
participants used aPCCand rFVIIa in the episodic group; in the prophy-
lactic group, however, aPCC was the most commonly used agent, con-
sistent with the fact that aPCC is the only product with a label for pro-
phylaxis in most countries.
Half of the participants had high adherence with prescribed aPCC
prophylaxis in terms of frequency of administration and prescribed
dose. The number of weekly administered prophylactic doses of aPCC
was high (median 7.45 doses/week), revealing a substantial burden of
treatment for these children and their caregivers. This burdenwas fur-
ther highlighted by the impairments in HRQoL reported by patients
and their caregivers in both treatment groups. Impairmentsweremain-
tained throughout the study, with little variation in scores between
the two groups. Despite adherence with aPCC prophylaxis, bleeding
rates were high and similar to those seen in the episodic group, high-
lighting a need for more effective treatment in this population. The
NIS provides data that differentiates between treated and all bleeds,
thus revealing that a substantial proportion of bleeds were untreated
in pediatric PwHA with inhibitors regardless of treatment regimen,
which may reflect the high treatment burden and limited efficacy of
BPAs.8,13-15
Bleed-related outcomes in adolescent/adult PwHA and FVIII
inhibitors in this NISwere previously reported.19 Differences between
the adolescent/adult and the pediatric populations were observed.
For treated bleeds, ABRs (model-based and median) were higher in
children versus adolescents/adults, with a greater difference between
the prophylactic groups than the episodic groups (Table S3). For
treated joint bleeds, the higher ABR observed in children versus
adolescents/adults may be explained by the different methods of data
collection for joint bleeds in these cohorts. For adolescents/adults,
reports of aura in combination with at least one other joint bleed
symptom (eg, increased swelling/warmth of the skin over the joint,
increased pain, progressive loss of range of motion, or difficulty using
the limb as compared with baseline) were required for a joint bleed
to be recorded. For children, suspected joint bleeds were recorded as
such regardless of the number of symptoms because it was not con-
sidered reliable to collect information from the caregiver on the joint
bleed symptoms in children. In addition, children may be more likely
to experience bleeds due to greater activity and a higher incidence of
trauma.
A greater proportion of pediatric participants adhered to aPCCpro-
phylaxis versus adolescents/adults (50% vs 35%),19 possibly due to
caregiver involvement in the pediatric cohort and recognition of the
importance of early prophylaxis to prevent joint damage.34-38 A dif-
ference in treatment burden was observed in children versus ado-
lescents/adults; median administered aPCC dose was 7.45 versus 3.0
doses/week, respectively. It should be noted, however, that these
results include aPCC doses used to treat bleeding events as well as
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F IGURE 2 Physical health domain scores over time for (A) Haemo-QoL SF and (B) Adapted Inhib-QoL. Baselinemeasurements were taken at
Week 1. High values in Haemo-QoL SF and Adapted Inhib-QoL imply high impairments in HRQoL. Adapted Inhib-QoL, Adapted Inhibitor-Specific
Quality of Life Assessment with Aspects of Caregiver Burden; Haemo-QoL SF, Haemophilia-Specific Quality of Life Assessment Instrument for
Children and Adolescents Short Form; HRQoL, health-related quality of life; SD, standard deviation
for usual prophylaxis, and the higher treatment burden in childrenmay
also be due to the higher treated bleed ABR in children (16.1) versus
adolescents/adults (8.8).19
Despite the prospective nature of this NIS and its granular data col-
lection methods, the interpretation of these results may potentially be
limited by study eligibility criteria. Participants were required to have
had a minimum number of bleeds during the 6 months prior to the
study; thus, investigators may have selected participants with signif-
icant bleeding on current standard therapy who they deemed would
benefit the most from emicizumab therapy in the subsequent Phase III
trial. Therefore, the study population was likely to include individuals
with a severe bleeding phenotype, and bleeding rates observed in this
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study may be an overestimate for the general population of pediatric
PwHA and inhibitors.
This NIS provides data on the current standard-of-care treat-
ment with episodic or prophylactic hemophilia regimens in pedi-
atric PwHA and inhibitors. Although the study inclusion criteria
required participants to have experienced a minimum number of
bleeds in the previous 6 months, reported outcomes showed high
bleeding rates despite high adherence to prophylaxis. These children
experienced a high treatment burden with numerous weekly infu-
sions and notable incidence of hemarthrosis, as well as concomi-
tant impairments in HRQoL, suggesting that there remains a sub-
stantial unmet need for improved treatment options in this patient
population.
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